Biotech Values

[iwfal]

Another thought is that if DNDN includes p-11 efficacy data and that data is good, then IMPACT becomes utterly meaningless. I think the FDA could tell DNDN to scrap IMPACT if p-11 is good. That could be another reason why DNDN is submitting p-11 efficacy. Scrapping IMPACT would save DNDN a lot of money for sure.

EagleEye is a nice guy but has a long history of completely unrealistic expectations. Look back a little over a year for what he was saying about NDA filing, ... . Also note that he does not understand anything at all about how drug trials work - e.g. saying that the FDA would "tell DNDN to scrap IMPACT if P-11 is good".